Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Kristina B. Emdal(Massachusetts Institute of Technology), Forest M. White(Center for Cancer Research), Antje Dittmann(University of Zurich), Raven J. Reddy(Massachusetts Institute of Technology), Sheri L. Moores(Harvard University), Sylvie Laquerre(Johnson & Johnson (United States)), Rebecca S. Lescarbeau(Massachusetts Institute of Technology)
Cited by 31
Related Papers
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
|Nature Biotechnology|2011|666